

CROSS-REFERENCE TO FORM 20-F

The information in this document that is referenced on this page is included in AstraZeneca's Form 20-F for 2007 (2007 Form 20-F) and is filed with the Securities and Exchange Commission (SEC). The 2007 Form 20-F is the only document intended to be incorporated by reference into any filings by AstraZeneca under the Securities Act of 1933, as amended. References to major headings include all information under such major headings, including subheadings. References to subheadings include only the information contained under such subheadings. Graphs are not included unless specifically identified. The 2007 Form 20-F has not been approved or disapproved by the SEC, nor has the SEC passed comment upon the accuracy or adequacy of the 2007 Form 20-F. The 2007 Form 20-F filed with the SEC may contain modified information and may be updated from time to time.

Item	Page	Item	Page	Item	Page
3 KEY INFORMATION		7 MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS		14 MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS	
A. Selected financial data		A. Major shareholders			n/a
Financial Highlights	2	Shareholder Information – Major shareholdings	187		
Group Financial Record	184	B. Related party transactions		15 CONTROLS AND PROCEDURES	
Shareholder Information	186	Shareholder Information – Related party transactions	188	Directors' Report – Internal controls, risk management and Turnbull Report guidance	42
D. Risk factors	193	Note 29 – Statutory and other information	175		
4 INFORMATION ON THE COMPANY		8 FINANCIAL INFORMATION		16 [RESERVED]	
A. History and development of the Company	200	A. Consolidated statements and other financial information		A. Audit Committee financial expert	
Financial Review – Investments, divestments and capital expenditure	82, 95	Financial Statements (excluding Directors' responsibilities on page 116 and Auditors' opinion on page 117)	118	Audit Committee	39
Note 8 – Property, plant and equipment	131	B. Significant changes		B. Code of ethics	
Note 24 – Acquisitions of business operations	145	Note 29 – Statutory and other information	175	Directors' Report – Code of Conduct	44
B. Business overview				C. Principal accountant fees and services	
Directors' Report	8			Note 29 – Statutory and other information	175
C. Organisational structure				D. Exemptions from the listing standards for audit committees	n/a
Directors' Report – Corporate Governance and Managing Risk	38			E. Purchases of equity securities by the issuer and affiliated purchasers	
Principal Subsidiaries	177			Note 30 – Share capital of parent company	176
D. Property, plant and equipment		9 THE OFFER AND LISTING		18 FINANCIAL STATEMENTS	
Directors' Report – Main Facilities	37	A4. Price history of listed stock		Financial Statements (excluding Directors' responsibilities on page 116 and Auditors' opinion on page 117)	118
		Shareholder Information	186		
		C. Markets			
		Shareholder Information	186		
		10 ADDITIONAL INFORMATION			
		B. Memorandum and Articles of Association	200		
		C. Material contracts	n/a		
		D. Exchange controls and other limitations affecting security holders	190		
		E. Taxation	85		
		H. Documents on display	189		
		I. Subsidiary information			
		Principal Subsidiaries	177		
		11 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK			
		Financial Review – Financial Risk Management Policies – Treasury	85		
		12 DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES			
					n/a
		13 DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES			
					n/a